

Wright Medical Group, Inc.
Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency
(dollars in thousands--unaudited)

	Three Months Ended June 30, 2011		Six Months Ended June 30, 2011	
	International Net Sales	Total Net Sales	International Net Sales	Total Net Sales
Net sales, as reported	\$ 57,151	\$ 132,505	\$ 114,595	\$ 267,891
Currency impact as compared to prior period	(4,824)	(4,824)	(6,566)	(6,566)
Net sales, excluding the impact of foreign currency	<u>\$ 52,327</u>	<u>\$ 127,681</u>	<u>\$ 108,029</u>	<u>\$ 261,325</u>

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	Three Months Ended		Six Months Ended	
	June 30, 2011	June 30, 2010	June 30, 2011	June 30, 2010
Operating Income				
Operating income, as reported	\$ 11,696	\$ 9,147	\$ 23,592	\$ 12,784
<i>Reconciling items impacting Gross Profit:</i>				
Non-cash, stock-based compensation	360	326	707	666
Total	<u>360</u>	<u>326</u>	<u>707</u>	<u>666</u>
<i>Reconciling items impacting Selling, General and Administrative expenses:</i>				
Non-cash, stock-based compensation	1,300	3,172	3,368	5,439
U.S. governmental inquiries/DPA related	2,385	606	4,567	8,677
Total	<u>3,685</u>	<u>3,778</u>	<u>7,935</u>	<u>14,116</u>
<i>Reconciling items impacting Research and Development expenses:</i>				
Non-cash, stock-based compensation	(53)	610	392	1,008
<i>Other Reconciling Items:</i>				
Restructuring charges	<u>-</u>	<u>461</u>	<u>-</u>	<u>1,005</u>
Operating income, as adjusted	<u>\$ 15,688</u>	<u>\$ 14,322</u>	<u>\$ 32,626</u>	<u>\$ 29,579</u>
Operating income, as adjusted, as a percentage of net sales	<u>11.8%</u>	<u>11.2%</u>	<u>12.2%</u>	<u>11.4%</u>

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(continued)

	Three Months Ended		Six Months Ended	
	June 30, 2011	June 30, 2010	June 30, 2011	June 30, 2010
Net Income				
Income before taxes, as reported	\$ 9,964	\$ 7,812	\$ 15,566	\$ 9,809
<i>Pre-tax impact of reconciling items:</i>				
Non-cash, stock-based compensation	1,607	4,108	4,467	7,113
Restructuring charges	-	461	-	1,005
Deferred financing fees and transaction costs associated with Convertible Notes Tender Offer	-	-	4,099	-
U.S. governmental inquiries/DPA related	2,385	606	4,567	8,677
Income before taxes, as adjusted	<u>13,956</u>	<u>12,987</u>	<u>28,699</u>	<u>26,604</u>
Provision for income taxes, as reported	3,817	2,965	5,827	5,487
Non-cash, stock-based compensation	219	1,314	1,066	2,150
Restructuring charges	-	180	-	391
Deferred financing fees and transaction costs associated with Convertible Notes Tender Offer	-	-	1,599	-
U.S. governmental inquiries/DPA related	930	236	1,782	1,816
Provision for income taxes, as adjusted	<u>4,966</u>	<u>4,695</u>	<u>10,274</u>	<u>9,844</u>
Effective tax rate, as adjusted	<u>35.6%</u>	<u>36.2%</u>	<u>35.8%</u>	<u>37.0%</u>
Net income, as adjusted	<u>\$ 8,990</u>	<u>\$ 8,292</u>	<u>\$ 18,425</u>	<u>\$ 16,760</u>

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(continued)

	Three Months Ended		Three Months Ended	
	June 30, 2011		June 30, 2010	
	<u>As Reported</u>	<u>As Adjusted</u>	<u>As Reported</u>	<u>As Adjusted</u>
Basic net income	\$ 6,147	\$ 8,990	\$ 4,847	\$ 8,292
Interest expense on convertible notes	137	137	N/A	935
Diluted net income	\$ 6,284	\$ 9,127	\$ 4,847	\$ 9,227
Basic shares	38,240	38,240	37,764	37,764
Dilutive effect of stock options and restricted shares	130	130	196	196
Dilutive effect of convertible notes	891	891	N/A	6,126
Diluted shares	39,261	39,261	37,960	44,086
Net income per share, diluted	<u>\$ 0.16</u>	<u>\$ 0.23</u>	<u>\$ 0.13</u>	<u>\$ 0.21</u>

	Six Months Ended		Six Months Ended	
	June 30, 2011		June 30, 2010	
	<u>As Reported</u>	<u>As Adjusted</u>	<u>As Reported</u>	<u>As Adjusted</u>
Basic net income	\$ 9,739	\$ 18,425	\$ 4,322	\$ 16,760
Interest expense on convertible notes	N/A	929	N/A	1,870
Diluted net income	\$ 9,739	\$ 19,354	\$ 4,322	\$ 18,630
Basic shares	38,137	38,137	37,652	37,652
Dilutive effect of stock options and restricted shares	210	210	232	232
Dilutive effect of convertible notes	N/A	2,927	N/A	6,126
Diluted shares	38,347	41,274	37,884	44,010
Net income per share, diluted	<u>\$ 0.25</u>	<u>\$ 0.47</u>	<u>\$ 0.11</u>	<u>\$ 0.42</u>

	Three Months Ended		Six Months Ended	
	<u>June 30, 2011</u>	<u>June 30, 2010</u>	<u>June 30, 2011</u>	<u>June 30, 2010</u>
	Net Income per Diluted Share			
Net income, as reported, per diluted share	\$ 0.16	\$ 0.13	\$ 0.25	\$ 0.11
Interest expense on convertible notes	N/A	0.02	0.02	0.04
Dilutive effect of convertible notes	N/A	(0.02)	(0.02)	(0.02)
Non-cash, stock-based compensation	0.04	0.06	0.08	0.11
Restructuring charges	-	0.01	-	0.01
Deferred financing fees and transaction costs associated with Convertible Notes Tender Offer	-	-	0.06	-
U.S. governmental inquiries/DPA related	0.04	0.01	0.07	0.16
Net income, as adjusted, per diluted share	<u>\$ 0.23</u>	<u>\$ 0.21</u>	<u>\$ 0.47</u>	<u>\$ 0.42</u>